Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521384 | 0.86 | FGFR1 (0.37) | FGFR1FGFR2FGFR4RPS6KA3FGFR3 | |
| SCHEMBL1521547 | 0.84 | RPS6KA3 (0.32) | FGFR1FGFR2FGFR4RPS6KA3FGFR3 | |
| SCHEMBL1521414 | 0.84 | FGFR4 (0.41) | FGFR1FGFR2FGFR4MAP4K1 | |
| SCHEMBL1521768 | 0.84 | FGFR1 (0.42) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL1521434 | 0.81 | FGFR4 (0.38) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL1522057 | 0.79 | NPC1 (0.39) | — | |
| SCHEMBL4273927 | 0.76 | BRAF (0.52) | — | |
| SCHEMBL1521668 | 0.76 | KDR (0.45) | — | |
| SCHEMBL30955654 | 0.76 | FGFR1 (0.34) | FGFR1FGFR2FGFR4CDK4CDK6 | |
| SCHEMBL1522002 | 0.75 | FGFR4 (0.49) | FGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | FGFR1 577/4885FGFR2 1106/4885FGFR4 1073/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | FGFR1 577/4885FGFR2 1106/4885FGFR4 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.